Applications for the vacant Brussels-based post of chief operating officer at the European Forum for GCP (EFGCP) are due to close on Friday August 18. EFGCP says it has earmarked a proposed start date of September 18 for the successful candidate.
The role will involve the following responsibilities:
According to the EFGCP, “The applicant should have strong self-motivation, interpersonal skills, be multi-tasks-oriented, possibly have experience in the healthcare sector and be able to work in a small team environment.”
It lists the job requirements as: experience in a coordination position and event organization; excellent written and oral communication skills in English (French is an asset); knowledge of financial management and bookkeeping and legal rules for associations based in Belgium; very well organized and caring for details; flexible, positive, and service-minded; excellent time management and respect of deadlines; and creative and resourceful problem-solving abilities.
Applications should include a CV in English and a one-page covering letter in English and be sent to jobs@efgcp.eu
Philip Ward is the European Editor for Applied Clinical Trials.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.